Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

A prognostic model to personalize monitoring regimes for patients with incidental asymptomatic meningiomas.

Islim AI, Kolamunnage-Dona R, Mohan M, Moon RDC, Crofton A, Haylock BJ, Rathi N, Brodbelt AR, Mills SJ, Jenkinson MD.

Neuro Oncol. 2019 Oct 11. pii: noz160. doi: 10.1093/neuonc/noz160. [Epub ahead of print]

PMID:
31603516
2.

TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral Therapy.

Pushpakom S, Kolamunnage-Dona R, Taylor C, Foster T, Spowart C, García-Fiñana M, Kemp GJ, Jaki T, Khoo S, Williamson P, Pirmohamed M; TAILoR Study Group .

Clin Infect Dis. 2019 Jul 3. pii: ciz589. doi: 10.1093/cid/ciz589. [Epub ahead of print]

PMID:
31425580
3.

Telmisartan to reduce insulin resistance in HIV-positive individuals on combination antiretroviral therapy: the TAILoR dose-ranging Phase II RCT.

Pushpakom S, Kolamunnage-Dona R, Taylor C, Foster T, Spowart C, Garcia-Finana M, Kemp GJ, Jaki T, Khoo S, Williamson P, Pirmohamed M.

Southampton (UK): NIHR Journals Library; 2019 Jul.

4.

Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT.

Ramanan AV, Dick AD, Jones AP, Hughes DA, McKay A, Rosala-Hallas A, Williamson PR, Hardwick B, Hickey H, Rainford N, Hickey G, Kolamunnage-Dona R, Culeddu G, Plumpton C, Wood E, Compeyrot-Lacassagne S, Woo P, Edelsten C, Beresford MW.

Health Technol Assess. 2019 Apr;23(15):1-140. doi: 10.3310/hta23150.

5.

Correction for Stott et al., "Population Pharmacokinetics and Cerebrospinal Fluid Penetration of Fluconazole in Adults with Cryptococcal Meningitis".

Stott KE, Beardsley J, Kolamunnage-Dona R, Castelazo AS, Kibengo FM, Mai NTH, Tùng NLN, Cuc NTK, Day J, Hope W.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e02254-18. doi: 10.1128/AAC.02254-18. Print 2018 Dec. No abstract available.

6.

Correction for Stott et al., "Population Pharmacokinetic Model and Meta-analysis of Outcomes of Amphotericin B Deoxycholate Use in Adults with Cryptococcal Meningitis".

Stott KE, Beardsley J, Whalley S, Mukasa Kibengo F, Mai NTH, Tùng NLN, Cuc NTK, Kolamunnage-Dona R, Hope W, Day J.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e02249-18. doi: 10.1128/AAC.02249-18. Print 2018 Dec. No abstract available.

7.

Population Pharmacodynamics of Amphotericin B Deoxycholate for Disseminated Infection Caused by Talaromyces marneffei.

Le T, Ly VT, Thu NTM, Nguyen A, Thanh NT, Chau NVV, Thwaites G, Perfect J, Kolamunnage-Dona R, Hope W.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01739-18. doi: 10.1128/AAC.01739-18. Print 2019 Feb.

8.

Investigation of one-stage meta-analysis methods for joint longitudinal and time-to-event data through simulation and real data application.

Sudell M, Kolamunnage-Dona R, Gueyffier F, Tudur Smith C.

Stat Med. 2019 Jan 30;38(2):247-268. doi: 10.1002/sim.7961. Epub 2018 Sep 12.

9.

Population Pharmacokinetics and Cerebrospinal Fluid Penetration of Fluconazole in Adults with Cryptococcal Meningitis.

Stott KE, Beardsley J, Kolamunnage-Dona R, Castelazo AS, Kibengo FM, Mai NTH, Tùng NLN, Cuc NTK, Day J, Hope W.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e00885-18. doi: 10.1128/AAC.00885-18. Print 2018 Sep. Erratum in: Antimicrob Agents Chemother. 2018 Nov 26;62(12):.

10.

joineRML: a joint model and software package for time-to-event and multivariate longitudinal outcomes.

Hickey GL, Philipson P, Jorgensen A, Kolamunnage-Dona R.

BMC Med Res Methodol. 2018 Jun 7;18(1):50. doi: 10.1186/s12874-018-0502-1.

11.

Time-dependent efficacy of longitudinal biomarker for clinical endpoint.

Kolamunnage-Dona R, Williamson PR.

Stat Methods Med Res. 2018 Jun;27(6):1909-1924. doi: 10.1177/0962280216673084. Epub 2016 Oct 17.

PMID:
29767590
12.

Correction: Antoniou, M.; et al. Fixed and Adaptive Parallel Subgroup-Specific Design for Survival Outcomes: Power and Sample Size. J. Pers. Med. 2017, 7, 19.

Antoniou M, Jorgensen AL, Kolamunnage-Dona R.

J Pers Med. 2018 May 7;8(2). pii: E18. doi: 10.3390/jpm8020018. No abstract available.

13.

Correction: Antoniou, M.; et al. Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review. J. Pers. Med. 2017, 7, 1.

Antoniou M, Kolamunnage-Dona R, Jorgensen AL.

J Pers Med. 2018 May 7;8(2). pii: E17. doi: 10.3390/jpm8020017. No abstract available.

14.

Population Pharmacokinetic Model and Meta-analysis of Outcomes of Amphotericin B Deoxycholate Use in Adults with Cryptococcal Meningitis.

Stott KE, Beardsley J, Whalley S, Kibengo FM, Mai NTH, Tùng NLN, Cuc NTK, Kolamunnage-Dona R, Hope W, Day J.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e02526-17. doi: 10.1128/AAC.02526-17. Print 2018 Jul. Erratum in: Antimicrob Agents Chemother. 2018 Nov 26;62(12):.

15.

Correction to: joint models for longitudinal and time-to-event data: a review of reporting quality with a view to meta-analysis.

Sudell M, Kolamunnage-Dona R, Tudur-Smith C.

BMC Med Res Methodol. 2018 Apr 4;18(1):33. doi: 10.1186/s12874-018-0489-7.

16.

Statistical primer: performing repeated-measures analysis.

Hickey GL, Mokhles MM, Chambers DJ, Kolamunnage-Dona R.

Interact Cardiovasc Thorac Surg. 2018 Apr 1;26(4):539-544. doi: 10.1093/icvts/ivy009. Review.

PMID:
29596693
17.

Joint Models of Longitudinal and Time-to-Event Data with More Than One Event Time Outcome: A Review.

Hickey GL, Philipson P, Jorgensen A, Kolamunnage-Dona R.

Int J Biostat. 2018 Jan 31;14(1). pii: /j/ijb.2018.14.issue-1/ijb-2017-0047/ijb-2017-0047.xml. doi: 10.1515/ijb-2017-0047. Review.

PMID:
29389664
18.

Investigation of 2-stage meta-analysis methods for joint longitudinal and time-to-event data through simulation and real data application.

Sudell M, Tudur Smith C, Gueyffier F, Kolamunnage-Dona R.

Stat Med. 2018 Apr 15;37(8):1227-1244. doi: 10.1002/sim.7585. Epub 2017 Dec 18.

19.

Fixed and Adaptive Parallel Subgroup-Specific Design for Survival Outcomes: Power and Sample Size.

Antoniou M, Jorgensen AL, Kolamunnage-Dona R.

J Pers Med. 2017 Dec 4;7(4). pii: E19. doi: 10.3390/jpm7040019. Erratum in: J Pers Med. 2018 May 07;8(2):.

20.

Pharmacodynamics of the Novel Antifungal Agent F901318 for Acute Sinopulmonary Aspergillosis Caused by Aspergillus flavus.

Negri CE, Johnson A, McEntee L, Box H, Whalley S, Schwartz JA, Ramos-Martín V, Livermore J, Kolamunnage-Dona R, Colombo AL, Hope WW.

J Infect Dis. 2018 Mar 13;217(7):1118-1127. doi: 10.1093/infdis/jix479. Erratum in: J Infect Dis. 2018 Apr 20;:.

21.

Pharmacodynamics of the Orotomides against Aspergillus fumigatus: New Opportunities for Treatment of Multidrug-Resistant Fungal Disease.

Hope WW, McEntee L, Livermore J, Whalley S, Johnson A, Farrington N, Kolamunnage-Dona R, Schwartz J, Kennedy A, Law D, Birch M, Rex JH.

MBio. 2017 Aug 22;8(4). pii: e01157-17. doi: 10.1128/mBio.01157-17.

22.

Predicting Risk of Serious Bacterial Infections in Febrile Children in the Emergency Department.

Irwin AD, Grant A, Williams R, Kolamunnage-Dona R, Drew RJ, Paulus S, Jeffers G, Williams K, Breen R, Preston J, Appelbe D, Chesters C, Newland P, Marzouk O, McNamara PS, Diggle PJ, Carrol ED.

Pediatrics. 2017 Aug;140(2). pii: e20162853. doi: 10.1542/peds.2016-2853. Epub 2017 Jul 5.

23.

Pharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response.

Kovanda LL, Kolamunnage-Dona R, Neely M, Maertens J, Lee M, Hope WW.

Clin Infect Dis. 2017 Jun 1;64(11):1557-1563. doi: 10.1093/cid/cix198. Erratum in: Clin Infect Dis. 2017 Oct 15;65(8):1431-1433.

24.

Time-dependent ROC curve analysis in medical research: current methods and applications.

Kamarudin AN, Cox T, Kolamunnage-Dona R.

BMC Med Res Methodol. 2017 Apr 7;17(1):53. doi: 10.1186/s12874-017-0332-6.

25.

Erratum to: Methods for evaluating medical tests and biomarkers.

Gopalakrishna G, Langendam M, Scholten R, Bossuyt P, Leeflang M, Noel-Storr A, Thomas J, Marshall I, Wallace B, Whiting P, Davenport C, Leeflang M, GopalaKrishna G, de Salis I, Mallett S, Wolff R, Whiting P, Riley R, Westwood M, Kleinen J, Collins G, Reitsma H, Moons K, Zapf A, Hoyer A, Kramer K, Kuss O, Ensor J, Deeks JJ, Martin EC, Riley RD, Rücker G, Steinhauser S, Schumacher M, Riley R, Ensor J, Snell K, Willis B, Debray T, Moons K, Deeks J, Collins G, di Ruffano LF, Willis B, Davenport C, Mallett S, Taylor-Phillips S, Hyde C, Deeks J, Mallett S, Taylor SA, Batnagar G; STREAMLINE COLON Investigators; STREAMLINE LUNG Investigators; METRIC Investigators, Taylor-Phillips S, Di Ruffano LF, Seedat F, Clarke A, Deeks J, Byron S, Nixon F, Albrow R, Walker T, Deakin C, Hyde C, Zhelev Z, Hunt H, di Ruffano LF, Yang Y, Abel L, Buchanan J, Fanshawe T, Shinkins B, Wynants L, Verbakel J, Van Huffel S, Timmerman D, Van Calster B, Leeflang M, Zwinderman A, Bossuyt P, Oke J, O'Sullivan J, Perera R, Nicholson B, Bromley HL, Roberts TE, Francis A, Petrie D, Mann GB, Malottki K, Smith H, Deeks J, Billingham L, Sitch A, Mallett S, Deeks J, Gerke O, Holm-Vilstrup M, Segtnan EA, Halekoh U, Høilund-Carlsen PF, Francq BG, Deeks J, Sitch A, Dinnes J, Parkes J, Gregory W, Hewison J, Altman D, Rosenberg W, Selby P, Asselineau J, Perez P, Paye A, Bessede E, Proust-Lima C, Naaktgeboren C, de Groot J, Rutjes A, Bossuyt P, Reitsma J, Moons K, Collins G, Ogundimu E, Cook J, Le Manach Y, Altman D, Wynants L, Vergouwe Y, Van Huffel S, Timmerman D, Van Calster B, Pajouheshnia R, Groenwold R, Moons K, Reitsma J, Peelen L, Van Calster B, Nieboer D, Vergouwe Y, De Cock B, Pencina MJ, Steyerberg EW, Cooper J, Taylor-Phillips S, Parsons N, Stinton C, Smith S, Dickens A, Jordan R, Enocson A, Fitzmaurice D, Sitch A, Adab P, Francq BG, Boachie C, Vidmar G, Freeman K, Connock M, Taylor-Phillips S, Court R, Clarke A, de Groot J, Naaktgeboren C, Reitsma H, Moons C, Harris J, Mumford A, Plummer Z, Lee K, Reeves B, Rogers C, Verheyden V, Angelini GD, Murphy GJ, Huddy J, Ni M, Good K, Cooke G, Bossuyt P, Hanna G, Ma J, Altman D, Collins G, Moons KGMC, de Groot JAH, Mallett S, Altman DG, Reitsma JB, Collins GS, Moons KGM, Altman DG, Reitsma JB, Collins GS, Kamarudin AN, Kolamunnage-Dona R, Cox T, Ni M, Huddy J, Borsci S, Hanna G, Pérez T, Pardo MC, Candela-Toha A, Muriel A, Zamora J, Sanghera S, Mohiuddin S, Martin R, Donovan J, Coast J, Seo MK, Cairns J, Mitchell E, Smith A, Wright J, Hall P, Messenger M, Calder N, Wickramasekera N, Vinall-Collier K, Lewington A, Pajouheshnia R, Damen J, Groenwold R, Moons K, Peelen L, Messenger M, Cairns D, Smith A, Hutchinson M, Wright J, Hall P, Calder N, Sturgeon C, Mitchel L, Kift R, Christakoudi S, Rungall M, Mobillo P, Montero R, Tsui TL, Kon SP, Tucker B, Sacks S, Farmer C, Strom T, Chowdhury P, Rebollo-Mesa I, Hernandez-Fuentes M, Damen JAAG, Debray TPA, Heus P, Hooft L, Moons KGM, Pajouheshnia R, Reitsma JB, Scholten RJPM, Damen JAAG, Hooft L, Schuit E, Debray TPA, Collins GS, Tzoulaki I, Lassale CM, Siontis GCM, Chiocchia V, Roberts C, Schlüssel MM, Gerry S, Black JA, Heus P, van der Schouw YT, Peelen LM, Moons KGM, Damen JAAG, Debray TPA, Heus P, Hooft L, Moons KGM, Pajouheshnia R, Reitsma JB, Scholten RJPM, Ma J, Altman D, Collins G, Spence G, McCartney D, van den Bruel A, Lasserson D, Hayward G, Vach W, de Jong A, Burggraaff C, Hoekstra O, Zijlstra J, de Vet H, Hunt H, Hyde C, Graziadio S, Allen J, Johnston L, O'Leary R, Power M, Allen J, Graziadio S, Johnson L, O'Leary R, Power M, Waters R, Simpson J, Johnston L, Allen J, Graziadio S, O'Leary R, Waters R, Power M, Mallett S, Fanshawe TR, Phillips P, Plumb A, Helbren E, Halligan S, Taylor SA, Gale A, Mallett S, Sekula P, Altman DG, Sauerbrei W, Mallett S, Fanshawe TR, Forman JR, Dutton SJ, Takwoingi Y, Hensor EM, Nichols TE, Shinkins B, Yang Y, Abel L, Di Ruffano LF, Fanshawe T, Kempf E, Porcher R, de Beyer J, Moons K, Altman D, Reitsma H, Hopewell S, Sauerbrei W, Collins G, Dennis J, Shields B, Jones A, Henley W, Pearson E, Hattersley A; MASTERMIND consortium, Heus P, Damen JAAG, Pajouheshnia R, Scholten RJPM, Reitsma JB, Collins GS, Altman DG, Moons KGM, Hooft L, Shields B, Dennis J, Jones A, Henley W, Pearson E, Hattersley A; MASTERMIND consortium, Scheibler F, Rummer A, Sturtz S, Großelfinger R, Banister K, Ramsay C, Azuara-Blanco A, Cook J, Boachie C, Burr J, Kumarasamy M, Bourne R, Uchegbu I, Borsci S, Murphy J, Hanna G, Uchegbu I, Carter A, Murphy J, Ni M, Marti J, Eatock J, Uchegbu I, Robotham J, Dudareva M, Gilchrist M, Holmes A, Uchegbu I, Borsci S, Monaghan P, Lord S, StJohn A, Sandberg S, Cobbaert C, Lennartz L, Verhagen-Kamerbeek W, Ebert C, Bossuyt P, Horvath A; Test Evaluation Working Group of the European Federation of Clinical Chemistry and Laboratory Medicine, Jenniskens K, Naaktgeboren C, Reitsma J, Moons K, de Groot J, Hyde C, Peters J, Grigore B, Peters J, Hyde C, Hyde C, Ukoumunne O, Peters J, Zhelev Z, Levis B, Benedetti A, Levis AW, Ioannidis JPA, Shrier I, Cuijpers P, Gilbody S, Kloda LA, McMillan D, Patten SB, Steele RJ, Ziegelstein RC, Bombardier CH, Osório FL, Fann JR, Gjerdingen D, Lamers F, Lotrakul M, Loureiro SR, Löwe B, Shaaban J, Stafford L, van Weert HCPM, Whooley MA, Williams LS, Wittkampf KA, Yeung AS, Thombs BD, Peters J, Cooper C, Buchanan J, Nieto T, Smith C, Tucker O, Dretzke J, Beggs A, Rai N, Davenport C, Bayliss S, Stevens S, Snell K, Mallet S, Deeks J, Sundar S, Hall E, Porta N, Estelles DL, de Bono J; CTC-STOP protocol development group.

Diagn Progn Res. 2017 Mar 30;1:11. doi: 10.1186/s41512-017-0011-4. eCollection 2017.

26.

Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.

Antoniou M, Kolamunnage-Dona R, Jorgensen AL.

J Pers Med. 2017 Jan 25;7(1). pii: E1. doi: 10.3390/jpm7010001. Review. Erratum in: J Pers Med. 2018 May 07;8(2):.

27.

Joint models for longitudinal and time-to-event data: a review of reporting quality with a view to meta-analysis.

Sudell M, Kolamunnage-Dona R, Tudur-Smith C.

BMC Med Res Methodol. 2016 Dec 5;16(1):168. doi: 10.1186/s12874-016-0272-6. Review. Erratum in: BMC Med Res Methodol. 2018 Apr 4;18(1):33.

28.

Laparoscopy-assisted gastrectomy in the elderly: experience from a UK centre.

Tandon A, Rajendran I, Aziz M, Kolamunnage-Dona R, Nunes QM, Shrotri M.

Ann R Coll Surg Engl. 2017 Apr;99(4):325-331. doi: 10.1308/rcsann.2016.0344. Epub 2016 Nov 21.

29.

Joint modelling of time-to-event and multivariate longitudinal outcomes: recent developments and issues.

Hickey GL, Philipson P, Jorgensen A, Kolamunnage-Dona R.

BMC Med Res Methodol. 2016 Sep 7;16(1):117. doi: 10.1186/s12874-016-0212-5.

30.

A Randomized Controlled Trial of Extended Brief Intervention for Alcohol-Dependent Patients in an Acute Hospital Setting.

Owens L, Kolamunnage-Dona R, Owens A, Perkins L, Butcher G, Wilson K, Beale S, Mahon J, Williamson P, Gilmore I, Pirmohamed M.

Alcohol Alcohol. 2016 Sep;51(5):584-92. doi: 10.1093/alcalc/agw023. Epub 2016 May 5.

PMID:
27151969
31.

Modelling variable dropout in randomised controlled trials with longitudinal outcomes: application to the MAGNETIC study.

Kolamunnage-Dona R, Powell C, Williamson PR.

Trials. 2016 Apr 28;17(1):222. doi: 10.1186/s13063-016-1342-0.

32.

Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.

Antoniou M, Jorgensen AL, Kolamunnage-Dona R.

PLoS One. 2016 Feb 24;11(2):e0149803. doi: 10.1371/journal.pone.0149803. eCollection 2016. Review.

33.

Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral therapy.

Pushpakom SP, Taylor C, Kolamunnage-Dona R, Spowart C, Vora J, García-Fiñana M, Kemp GJ, Whitehead J, Jaki T, Khoo S, Williamson P, Pirmohamed M.

BMJ Open. 2015 Oct 15;5(10):e009566. doi: 10.1136/bmjopen-2015-009566.

34.

Economic evaluation of nebulized magnesium sulphate in acute severe asthma in children.

Petrou S, Boland A, Khan K, Powell C, Kolamunnage-Dona R, Lowe J, Doull I, Hood K, Williamson P.

Int J Technol Assess Health Care. 2014 Oct;30(4):354-60. doi: 10.1017/S0266462314000440. Epub 2014 Nov 14.

PMID:
25394502
35.

Calprotectin and lactoferrin faecal levels in patients with Clostridium difficile infection (CDI): a prospective cohort study.

Swale A, Miyajima F, Roberts P, Hall A, Little M, Beadsworth MB, Beeching NJ, Kolamunnage-Dona R, Parry CM, Pirmohamed M.

PLoS One. 2014 Aug 29;9(8):e106118. doi: 10.1371/journal.pone.0106118. eCollection 2014.

36.

Serum mannose-binding lectin concentration, but not genotype, is associated with Clostridium difficile infection recurrence: a prospective cohort study.

Swale A, Miyajima F, Kolamunnage-Dona R, Roberts P, Little M, Beeching NJ, Beadsworth MB, Liloglou T, Pirmohamed M.

Clin Infect Dis. 2014 Nov 15;59(10):1429-36. doi: 10.1093/cid/ciu666. Epub 2014 Aug 28.

37.

A review of the handling of missing longitudinal outcome data in clinical trials.

Powney M, Williamson P, Kirkham J, Kolamunnage-Dona R.

Trials. 2014 Jun 19;15:237. doi: 10.1186/1745-6215-15-237. Review.

38.

Is the interleukin 8 promoter polymorphism rs4073/-251T >A associated with Clostridium difficile infection?

Miyajima F, Swale A, Zhang JE, Alfirevic A, Little M, Beeching NJ, Smith G, Kolamunnage-Dona R, Pirmohamed M.

Clin Infect Dis. 2014 Jun;58(12):e148-51. doi: 10.1093/cid/ciu152. Epub 2014 Mar 14.

PMID:
24633688
39.

Magnesium sulphate in acute severe asthma in children (MAGNETIC): a randomised, placebo-controlled trial.

Powell C, Kolamunnage-Dona R, Lowe J, Boland A, Petrou S, Doull I, Hood K, Williamson P; MAGNETIC study group.

Lancet Respir Med. 2013 Jun;1(4):301-8. doi: 10.1016/S2213-2600(13)70037-7. Epub 2013 Apr 22. Erratum in: Lancet Respir Med. 2013 Jun;1(4):285.

PMID:
24429155
40.

MAGNEsium Trial In Children (MAGNETIC): a randomised, placebo-controlled trial and economic evaluation of nebulised magnesium sulphate in acute severe asthma in children.

Powell CV, Kolamunnage-Dona R, Lowe J, Boland A, Petrou S, Doull I, Hood K, Williamson PR; MAGNETIC study group.

Health Technol Assess. 2013 Oct;17(45):v-vi, 1-216. doi: 10.3310/hta17450.

41.

Antidepressant medication in patients with advanced cancer--an observational study.

Lloyd-Williams M, Payne S, Reeve J, Kolamunnage Dona R.

QJM. 2013 Nov;106(11):995-1001. doi: 10.1093/qjmed/hct133. Epub 2013 Jun 3.

PMID:
23737506
42.

Assessment and clinical course of hypocalcemia in critical illness.

Steele T, Kolamunnage-Dona R, Downey C, Toh CH, Welters I.

Crit Care. 2013 Jun 4;17(3):R106. doi: 10.1186/cc12756.

43.

Novel biomarker combination improves the diagnosis of serious bacterial infections in Malawian children.

Irwin AD, Marriage F, Mankhambo LA; IPD Group Study, Jeffers G, Kolamunnage-Dona R, Guiver M, Denis B, Molyneux EM, Molyneux ME, Day PJ, Carrol ED.

BMC Med Genomics. 2012 May 4;5:13. doi: 10.1186/1755-8794-5-13.

44.

A randomised controlled trial of extended brief intervention for alcohol dependent patients in an acute hospital setting (ADPAC).

Owens L, Butcher G, Gilmore I, Kolamunnage-Dona R, Oyee J, Perkins L, Walley T, Williamson P, Wilson K, Pirmohamed M.

BMC Public Health. 2011 Jul 4;11:528. doi: 10.1186/1471-2458-11-528.

45.

Brief interventions in dependent drinkers: a comparative prospective analysis in two hospitals.

Cobain K, Owens L, Kolamunnage-Dona R, Fitzgerald R, Gilmore I, Pirmohamed M.

Alcohol Alcohol. 2011 Jul-Aug;46(4):434-40. doi: 10.1093/alcalc/agr044. Epub 2011 May 12.

PMID:
21565842
46.

Depressive and manic symptoms are not opposite poles in bipolar disorder.

Johnson SL, Morriss R, Scott J, Paykel E, Kinderman P, Kolamunnage-Dona R, Bentall RP.

Acta Psychiatr Scand. 2011 Mar;123(3):206-10. doi: 10.1111/j.1600-0447.2010.01602.x. Epub 2010 Sep 5.

47.

Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention.

Greenhalgh J, Bagust A, Boland A, Saborido CM, Fleeman N, McLeod C, Dundar Y, Dickson R, Proudlove C, Kolamunnage-Dona R, Fisher M.

Health Technol Assess. 2010 May;14 Suppl 1:31-8. doi: 10.3310/hta14Suppl1/05. Review.

48.

Assessing the potential for outcome reporting bias in a review: a tutorial.

Dwan K, Gamble C, Kolamunnage-Dona R, Mohammed S, Powell C, Williamson PR.

Trials. 2010 May 12;11:52. doi: 10.1186/1745-6215-11-52.

49.

Enhanced relapse prevention for bipolar disorder by community mental health teams: cluster feasibility randomised trial.

Lobban F, Taylor L, Chandler C, Tyler E, Kinderman P, Kolamunnage-Dona R, Gamble C, Peters S, Pontin E, Sellwood W, Morriss RK.

Br J Psychiatry. 2010 Jan;196(1):59-63. doi: 10.1192/bjp.bp.109.065524.

PMID:
20044662
50.

Patients with epilepsy: cognitively compromised before the start of antiepileptic drug treatment?

Taylor J, Kolamunnage-Dona R, Marson AG, Smith PE, Aldenkamp AP, Baker GA; SANAD study group.

Epilepsia. 2010 Jan;51(1):48-56. doi: 10.1111/j.1528-1167.2009.02195.x. Epub 2009 Jul 2.

Supplemental Content

Loading ...
Support Center